Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsMing Yi, Kongming Wu|Molecular Cancer|2022Cited by 1.4k
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapyYuze Wu, Kongming Wu|Molecular Cancer|2022Cited by 458
Chimeric antigen receptor T cells: a novel therapy for solid tumorsShengnan Yu, Kongming Wu|Journal of Hematology & Oncology|2017Cited by 306
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicityShengnan Yu, Kongming Wu|Molecular Cancer|2019Cited by 266
Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumorsMing Yi, Kongming Wu, Qian Chu et al.|Journal of Hematology & Oncology|2022Cited by 178